Third‐line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource‐limited settings: ACTG A5288 strategy trial

Anchalee Avihingsanon, Michael D. Hughes, Robert A. Salata et al.|Journal of the International AIDS Society|2022

Cited by 13